SEARCH

SEARCH BY CITATION

References

  • 1
    Klein MB, Lu Y, DelBalso L, Coté S, Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007; 45: 234240.
  • 2
    Klein MB, Yang H, DelBalso L, Carbonneau J, Frost E, Boivin G. Viral pathogens including human metapneumovirus are the primary cause of febrile respiratory illness in HIV-infected adults receiving antiretroviral therapy. J Infect Dis 2010; 201: 297301.
  • 3
    Cohen JP, Macauley C. Susceptibility to influenza A in HIV-positive patients. JAMA 1989; 261: 245.
  • 4
    Thurn JR, Henry K. Influenza A pneumonitis in a patient infected with the human immunodeficiency virus infection. Chest 1989; 95: 807810.
  • 5
    Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990; 98: 3337.
  • 6
    Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immunodeficiency virus-infected patients during the 1997–1998 influenza season. Clin Infect Dis 2000; 31: 604606.
  • 7
    Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281: 901907.
  • 8
    Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161: 441446.
  • 9
    Kuniasaki Km, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9: 493504.
  • 10
    Centers for Disease Control and Prevention. Recommended adult immunization schedule – United States, 2009. Morbid Mortal Wkly Rep 2009; 57: Q-1Q-4.
  • 11
    Clinical protocol for the WHO European region. Immunization of people living with HIV and people at risk of HIV infection. Available at http://www.euro.who.int/document/SHA/e90840_chapter_12.pdf (accessed 24 August 2010).
  • 12
    Guidance: priority risk groups for influenza vaccination. Stockholm, August 2008. Available at http://www.ecdceuropa.eu/en/publications/Publications/0808_GUI_Priority_Risk_Groups_for_Influenza_Vaccination.pdf (accessed 24 August 2010).
  • 13
    Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 26052615.
  • 14
    Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361: 680689.
  • 15
    Chan M. World now at the start of 2009 influenza pandemic. Available at http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html (accessed 24 August 2010).
  • 16
    Collignon P. Take a deep breath: swine flu is not that bad. Aust Emer Nurs J 2009; 12: 7172.
  • 17
    SteelFisher GK, Blendon RJ, Bekheit MM, Lubell K. The public's response to the 2009 H1N1 influenza pandemic. N Engl J Med 2010; 362: e65.
  • 18
    Presanis AM, De Angelis D, The New York City Swine Flu Investigation Team et al. The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. PLoS Med 2009; 6: e1000207.
  • 19
    Louie J, Winter K, Harriman K et al. Hospitalized patients with novel influenza A (H1N1) virus infection – California, April-May, 2009. Morbid Mortal Wkly Rep 2009; 58 (early release): 15.
  • 20
    Domínguez-Cherit G, Lapinsky SE, Macias AE et al. Critically ill patients with 2009 influenza A (H1N1) in Mexico. JAMA 2009; 302: 18801887.
  • 21
    Vaillant L, La Ruche G, Tarantola A, Barboza P, for the epidemic intelligence team at InVS. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 2009; 14: pii=19309.
  • 22
    World Health Organization. Considerations on influenza A (H1N1) and HIV infection. Available at http://www.who.int/hiv/mediacentre/influenza_hiv.pdf (accessed 24 August 2010).
  • 23
    Centers for Disease Control and Prevention. 2009 H1N1 and people with HIV/AIDS. Available at http://www.cdc.gov/h1n1flu/People_with_HIVAIDS.htm (accessed 29 July 2010).
  • 24
    Ministerio de Sanidad y Política Social. Recomendaciones. Available at http://www.informaciongripea.es/recomendaciones.html (accessed 24 August 2010).
  • 25
    Lampe FC, Gatell JM, Staszewski S et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166: 521528.
  • 26
    Rodriguez E, Gallo de Puelles P, Jovell AL. The Spanish health care system: lessons from newly industrialized countries. Health Policy Plann 1999; 14: 164173.
  • 27
    Ministerio de Sanidad y Política Social. Recomendaciones para profesionales de atención primaria sobre el manejo diagnóstico y terapéutico de la infección por el virus pandémico (H1N1) 2009 y la organización de la asistencia. Available at http://www.msps.es/profesionales/saludPublica/gripeA/guiasProtocolosInf/profSanit.htm (accessed 24 August 2010).
  • 28
    Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009–2010 season. Available at http://www.cdc.gov/h1n1flu/recommendations.htm (accessed 24 August 2010).
  • 29
    World Health Organization. Clinical management of human infection with pandemic (H1N1) 2009: revised guidance. Available at http://www.who.int/csr/resources/publications/swineflu/clinical_management/en/index.html (accessed 24 August 2010).
  • 30
    World Health Organization. CDC protocol of realtime RTPCR for swine influenza A (H1N1). Revision 1 (30 April 2009). Available at http://www.who.int/csr/resources/publications/swineflu/CDCrealtimeRTPCRprotocol_20090428.pdf (accessed 24 August 2010).
  • 31
    Monitorización de la prevalencia del VIH. In: Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT). SIVES 2008: Sistema Integrado de Vigilancia Epidemiológica del SIDA/VIH/ITS en Catalunya (SIVES) : Informe bianual. Barcelona : Generalitat de Catalunya, Departament de Salut, 2008. Available at http://www.ceescat.org/Documents/SIVES_2008_ESP_prevalVIH.pdf (accessed 24 August 2010).
  • 32
    Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 17081719.
  • 33
    Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev 2009; 11: 3038.
  • 34
    Girardi E, Sabin CA, d'Arminio Monforte A. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46: S3S8.
  • 35
    Tarwater PM, Margolick JB, Jin J et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 168175.
  • 36
    Garcia F, de Lazzari E, Plana M et al. Long-term CD4+T-cell response to highly active antiretroviral therapy according to baseline CD4+T-cell count. J Acquir Immune Defic Syndr 2004; 36: 702713.
  • 37
    Gras L, Kesselring AM, Griffin JT et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007; 45: 183192.
  • 38
    Moore RD, Keruly JC. CD4+cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44: 441446.
  • 39
    Hirschtick RE, Glassroth J, Jordan MC et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995; 333: 845851.
  • 40
    Tumbarello M, Tacconelli E, de Gaetano K et al. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J Acquir Immune Defic Syndr 1998; 18: 3945.
  • 41
    Burns DN, Hillman D, Neaton JD et al. Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. J Acquir Immune Defic Syndr 1996; 13: 374383.
  • 42
    Reyes-Terán G, de la Rosa-Zamboni D, Ormsby C et al. Clinical features of subjects infected with HIV and H1N1 influenza virus. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2010 [Abstract 803LB].
  • 43
    Klein NC, Chak A, Chengot M, Johnson DH, Cunha BA. Fatal case of pneumonia associated with pandemic (H1N1) 2009 in HIV-positive patient. Emerg Infect Dis 2010; 16: 149150.
  • 44
    Mora M, Rodriguez-Castellano E, Pano-Pardo J et al. Influenza A pandemic (H1N1) 2009 virus and HIV. Emerg Infect Dis 2010; 16: 11751176.
  • 45
    Campos-Loza A, Soto-Ramirez L, Sierra-Madero J et al. New Swine Origin Influenza A in HIV-infected Patients during the 2009 Outbreak in Mexico City. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2010 [Abstract 801].
  • 46
    Sanchez Conde M, Miralles Martin P, Ramirez Schacke M et al. Brote de influenza A H1N1 en una unidad de hospitalización VIH. XIV Congreso de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Barcelona, Spain, May 2010 [Abstract 118].
  • 47
    Golden MP, Sajjad Z, Elgart L. Influenza and human immunodeficiency virus infection: absence of HIV progression after acute influenza infection. Clin Infect Dis 2001; 32: 13661370.
  • 48
    Bickel M, Wieters I, Khaykin P et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010; 24: F31F35.
  • 49
    Tebas P, Frank I, Lewis M et al. Poor immunogenicity of the H1N1 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24: 21872192.